Wu L - Search Results

1

RUFY3 interaction with FOXK1 promotes invasion and metastasis in colorectal cancer.

Xie R, Wang J, Liu X, Wu L, Zhang H, Tang W, Li Y, Xiang L, Peng Y, Huang X, Bai Y, Liu G, Li A, Wang Y, Chen Y, Ren Y, Li G, Gong W, Liu S, Wang J. Xie R, et al. Among authors: wu l. Sci Rep. 2017 Jun 16;7(1):3709. doi: 10.1038/s41598-017-04011-1. Sci Rep. 2017. PMID: 28623323 Free PMC article.

2

Coexpression of FOXK1 and vimentin promotes EMT, migration, and invasion in gastric cancer cells.

Zhang H, Wu X, Xiao Y, Wu L, Peng Y, Tang W, Liu G, Sun Y, Wang J, Zhu H, Liu M, Zhang W, Dai W, Jiang P, Li A, Li G, Xiang L, Liu S, Wang J. Zhang H, et al. Among authors: wu x, wu l. J Mol Med (Berl). 2019 Feb;97(2):163-176. doi: 10.1007/s00109-018-1720-z. Epub 2018 Nov 27. J Mol Med (Berl). 2019. PMID: 30483822

3

Paranasal sinus invasion suggested T4 classification of patients of nasopharyngeal carcinoma: A two-center retrospective investigation.

Wu L, Zhuo S, Zeng W, Liang S, Wang S, Cui C, Zhou J, Ruan G, Xu S, Wang L, Huang L, Liu L, Li H. Wu L, et al. Head Neck. 2019 Dec;41(12):4088-4097. doi: 10.1002/hed.25953. Epub 2019 Sep 13. Head Neck. 2019. PMID: 31518030

4

Pseudoangiosarcomatous squamous cell carcinoma: a rare subtype of squamous cell carcinoma that needs to be differentiated from angiosarcoma and has a poor prognosis.

Zhan Y, Wan H, Wu L, Ge X, Xie X, Wu L, Cai Y. Zhan Y, et al. Among authors: wu l. Cell Mol Biol (Noisy-le-grand). 2022 Jun 30;68(6):62-66. doi: 10.14715/cmb/2022.68.6.10. Cell Mol Biol (Noisy-le-grand). 2022. PMID: 36227677

5

Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study.

Zhang Y, Zhou H, Duan M, Gao S, He G, Jing H, Li J, Ma L, Zhu H, Chang C, Du X, Hong M, Li X, Liu Q, Wang W, Xu N, Yang H, Lu B, Yin H, Wu L, Suo S, Zhao Q, Xiao Z, Jin J. Zhang Y, et al. Among authors: wu l. Am J Hematol. 2023 Oct;98(10):1588-1597. doi: 10.1002/ajh.27033. Epub 2023 Jul 20. Am J Hematol. 2023. PMID: 37470365 Clinical Trial.

6

Establishment and validation of novel MRI radiomic feature-based prognostic models to predict progression-free survival in locally advanced rectal cancer.

Xie F, Zhao Q, Li S, Wu S, Li J, Li H, Chen S, Jiang W, Dong A, Wu L, Liu L, Huang H, Xu S, Shao Y, Liu L, Li L, Cai P. Xie F, et al. Among authors: wu s, wu l. Front Oncol. 2022 Nov 3;12:901287. doi: 10.3389/fonc.2022.901287. eCollection 2022. Front Oncol. 2022. PMID: 36408187 Free PMC article.

7

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.

Qin S, Bi F, Gu S, Bai Y, Chen Z, Wang Z, Ying J, Lu Y, Meng Z, Pan H, Yang P, Zhang H, Chen X, Xu A, Cui C, Zhu B, Wu J, Xin X, Wang J, Shan J, Chen J, Zheng Z, Xu L, Wen X, You Z, Ren Z, Liu X, Qiu M, Wu L, Chen F. Qin S, et al. Among authors: wu l, wu j. J Clin Oncol. 2021 Sep 20;39(27):3002-3011. doi: 10.1200/JCO.21.00163. Epub 2021 Jun 29. J Clin Oncol. 2021. PMID: 34185551 Free PMC article. Clinical Trial.

8

Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer.

Lin Y, Qin S, Yang H, Shi F, Yang A, Han X, Liu B, Li Z, Ji Q, Tang L, Deng Z, Ding Y, Fu W, Xie X, Li L, He X, Lv Z, Ma Q, Shen Z, Guo Z, Chen Z, Cui Y, Tan J, Gao Z, Jing S, Lu K, Luo X, Zhang Y, Fang Y, Li Z, Cheng Y, Lei S, Luan S, Chen G, Wang G, Wu L, Liu L. Lin Y, et al. Among authors: wu l. Clin Cancer Res. 2023 Aug 1;29(15):2791-2799. doi: 10.1158/1078-0432.CCR-22-3613. Clin Cancer Res. 2023. PMID: 37184934 Clinical Trial.

9

Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naïve patients with myelofibrosis: Results of a phase II trial.

Zhang Y, Zhou H, Jiang Z, Wu D, Zhuang J, Li W, Jiang Q, Wang X, Huang J, Zhu H, Yang L, Du X, Li F, Xia R, Zhang F, Hu J, Li Y, Hu Y, Liu J, Jin C, Sun K, Zhou Z, Wu L, Yu W, Jin J. Zhang Y, et al. Among authors: wu d, wu l. Am J Hematol. 2022 Dec;97(12):1510-1519. doi: 10.1002/ajh.26709. Epub 2022 Oct 4. Am J Hematol. 2022. PMID: 36054786 Free PMC article. Clinical Trial.

10

Correction: Comprehensive risk factor predictions for 3-year survival among HIV-associated and disseminated cryptococcosis involving lungs and central nervous system.

Wu L, Fu X, Pütz B, Zhang R, Liu L, Song W, Weng L, Shao Y, Zheng Z, Xun J, Han X, Wang T, Shen Y, Lu H, Müller-Myhsok B, Chen J. Wu L, et al. Infection. 2024 May 17. doi: 10.1007/s15010-024-02281-2. Online ahead of print. Infection. 2024. PMID: 38758488 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

30,689 results

Search Page